Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

about

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.

P2860

Q54976637-961D63E1-BA5D-4823-AC8B-74269E1D5285

P2860

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

Item

http://www.wikidata.org/entity/Q39288497

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

@en

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

@nl

type

Item

label

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

@en

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

@nl

prefLabel

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

@en

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

@nl

P1476

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

@en

P2093

Alfonso García-Valverde

http://www.w3.org/2001/XMLSchema#string

Claudia Valverde

http://www.w3.org/2001/XMLSchema#string

Cristina Suárez

http://www.w3.org/2001/XMLSchema#string

César Serrano

http://www.w3.org/2001/XMLSchema#string

David Olivares

http://www.w3.org/2001/XMLSchema#string

Rafael Morales-Barrera

http://www.w3.org/2001/XMLSchema#string

Suzanne George

http://www.w3.org/2001/XMLSchema#string

P2860

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

P2888

s11523-017-0490-9

P304

277-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-017-0490-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joan Carles Galcerán

P577

2017-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28478525

http://www.w3.org/2001/XMLSchema#string

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

about

P2860

P2860

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698